Aktis Oncology, Inc.
Aktis Oncology is a clinical-stage oncology company developing targeted radiopharmaceuticals for cancer patients. Its proprietary miniprotein radioconjugate platform is designed to deliver imaging or therapeutic radioisotopes to tumors. The company’s lead candidate, [225Ac]Ac-AKY-1189, targets Nectin-4-expressing tumors, including urothelial, breast, lung, colorectal and cervical cancers. Its second candidate, [225Ac]Ac-AKY-2519, targets B7-H3-expressing tumors, including prostate, lung and breast cancers. Aktis also has several unpartnered programs in discovery and a collaboration with Eli Lilly to generate radiopharmaceuticals against selected targets. Aktis is developing its candidates through clinical trials and supports its work with radiopharmaceutical development and manufacturing capabilities, isotope supply agreements and contract manufacturing partners. It is also building an internal cGMP facility. Under the Eli Lilly collaboration, Aktis conducts discovery through initial human imaging studies; Eli Lilly is responsible for clinical development and commercialization from Phase 1 onward. Aktis Oncology is headquartered in Boston, Massachusetts.
No SEC Form 4 filings for $AKTS in the last 30 days.
See all $AKTS insider activity →Aktis Oncology reported 3Q 2026 revenue of $3.91M, up 147% YoY, but net loss widened to $29.94M due to increased R&D and employee costs. Clinical programs AKY-2519 and AKY-1189 saw higher spending, while collaboration revenue from Eli Lilly was $3.9M. Cash reserves totaled $492.9M, expected to fund operations into 2029.
Aktis Oncology, Inc. (AKTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress • Initiated the Company’s third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumors • Started first backfill coho
Wedbush maintained an Outperform rating on Aktis Oncology, setting a $35 price target, suggesting an 89% upside from the Oct 1 close. The firm cited strong clinical data for AKY-1189 and AKY-2519, and upcoming study milestones as key drivers.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning AKTS (Aktis Oncology, Inc.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 2 bearish.
Recent AKTS coverage spans earnings, financial news and sector analysis.
Earnings miss with higher loss likely pressures the stock lower.
New earnings numbers and clinical trial initiations could move the stock as investors price the cash runway and upcoming data.
Analyst upgrade may lift the stock as investors price in higher target.
The trial start adds a new catalyst that could lift the stock if early data are positive.
Positive rating may support stock.
AlphAI scores every news story that mentions AKTS with an AI model for sentiment and relevance, and aggregates insider trades from Aktis Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aktis Oncology reported 3Q 2026 revenue of $3.91M, up 147% YoY, but net loss widened to $29.94M due to increased R&D and employee costs. Clinical programs AKY-2519 and AKY-1189 saw higher spending, while collaboration revenue from Eli Lilly was $3.9M. Cash reserves totaled $492.9M, expected to fund operations into 2029.
Aktis Oncology, Inc. (AKTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress • Initiated the Company’s third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumors • Started first backfill coho
Wedbush maintained an Outperform rating on Aktis Oncology, setting a $35 price target, suggesting an 89% upside from the Oct 1 close. The firm cited strong clinical data for AKY-1189 and AKY-2519, and upcoming study milestones as key drivers.
Aktis Oncology (NASDAQ:AKTS) began a Phase 1b trial for AKY-2519 in lung cancer and other solid tumors. The multicenter study will test three dose levels. The company also has ongoing trials for prostate cancer and Nectin-4 expressing tumors, with data expected in 2027. Aktis develops targeted radioconjugates and collaborates with Eli Lilly.
Analysts made several rating changes: TD Cowen initiated Faeth Therapeutics as buy, Barclays upgraded Sagimet Biosciences to overweight, JPMorgan upgraded Lithium Americas to overweight, and more. Price targets were also adjusted for companies like Affirm, Robinhood, and First Solar.
Bank of America cited a July selloff in AI stocks and named 16 “oversold” picks it rates Buy and Top Pick, each down at least 20% from 52-week highs. Examples include Oracle (ORCL) down 55% and CoreWeave (CRWV) down 31%. BofA also listed 12-month price targets, including MU $1,550 (+63%) and ORCL $240 (+54%).
Bank of America said its AI-infrastructure stock screen found 16 Buy-rated names trading more than 20% below 52-week highs, with positive three-month earnings revisions. Micron (MU) had the largest implied upside versus BofA’s $1,550 target, about 63%. BofA cited server DRAM pricing growth and tight supply, plus long-term 2028 EPS estimate near $150.
Aktis Oncology, Inc. (AKTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 • Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing so
Herrmann Ken sold 4,856 shares of Aktis Oncology, Inc. (AKTS) at $24.56 ($0.12M total) across 2 trades on 2026-07-20.
Ron-Bigger Shulamit (Chief Operating Officer) sold 50,000 shares of Aktis Oncology, Inc. (AKTS) at an average of $27.75 ($27.13–$28.75, $1.39M total) across 3 trades on 2026-07-08.
